EFTR240621P2500
- 2.14
- 0.000.00%
eFFECTOR Therapeutics Newsroom
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersSharps Technology (NASDAQ:STSS) shares rose 193.0% to $0.63 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.8 million. Insmed (NASDAQ:INSM) shares mov
Express News | EFFECTOR Therapeutics And Dana-Farber Cancer Institute To Collaborate On Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin As Combination Treatment In ER+ Endometrial Cancer And In Low Grade Serous Ovarian Cancer
Express News | EFFECTOR Therapeutics : Anticipate Determination of Phase 2 Dose (Rp2D) of Zotatifin in Combination With Fulvestrant & Abemaciclib, in H2 2024
Express News | EFFECTOR Therapeutics to Collaborate With the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in Er+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
Express News | EFFECTOR Therapeutics Inc: Terminated Its Controlled Equity Offering Sales Agreement, Dated Sept 1, 2022, With Cantor Fitzgerald & Co
Express News | EFFECTOR Therapeutics: Under Agreement, Co May, From Time to Time, Sell Shares of Co's Common Stock Having Offering Price of up to $50 Mln
Express News | EFFECTOR Therapeutics Inc: Entered Into an at the Market Offering Agreement With H.c. Wainwright & Co., LLC
EFFECTOR Therapeutics Q1 2024 GAAP EPS $(2.16) Beats $(2.17) Estimate; Reports Cash Runway Into Q1 Of 2025
eFFECTOR Therapeutics (NASDAQ:EFTR) reported quarterly losses of $(2.16) per share which beat the analyst consensus estimate of $(2.17) by 0.46 percent.
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersSensus Healthcare (NASDAQ:SRTS) shares increased by 33.3% to $5.08 during Thursday's after-market session. The market value of their outstanding shares is at $83.2 million. As per the news, the
10-Q: Quarterly report
Express News | EFFECTOR Therapeutics Q1 Operating Expenses USD 8.396 Million
Express News | EFFECTOR Therapeutics Q1 Net Income USD -8.834 Million
Press Release: EFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024
EFFECTOR Therapeutics to Participate in Upcoming Investor Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitor
Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), UniQure (QURE) and EFFECTOR Therapeutics (EFTR)
12 Health Care Stocks Moving In Friday's Intraday Session
GainersCandel Therapeutics (NASDAQ:CADL) stock increased by 27.6% to $8.17 during Friday's regular session. The company's market cap stands at $239.6 million. Galectin Therapeutics (NASDAQ:GALT) share
Analysts Offer Insights on Healthcare Companies: EFFECTOR Therapeutics (EFTR), Adagene (ADAG) and Aquestive Therapeutics (AQST)
Trending Stocks Today: Candel Therapeutics Shoots up 121.64%
April 4th - US stocks trending in regular trading hours.Gainers: $Candel Therapeutics(CADL.US)$ shoots up 121.64% to $3.72 with a turnover of $214.01 million. $Allurion Technologies(ALUR.US)$ surges 9
Top Midday Decliners
eFFECTOR Therapeutics (EFTR) Chief Executive Officer Steve Worland said there is no "obvious path forward to continue developing tomivosertib in frontline NSCLC" based on the data currently available
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of STAAR Surgical Company (NASDAQ:STAA) rose sharply during Thursday's session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%